HTN event was noted in 73 in the BRAF monotherapy arm versus 19 patients in the BRAF/MEK combination arm (6‐month rate 7.1% (CI: 5.1%–10.0%) versus 11.3% (CI: 5.7–22.7%); Figure 3C). The gene discussed is BRAF; the disease is hypertensive disorder.